Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KRYS 
Krystal Biotech Inc (KRYS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: KRYS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $205.2
1 Year Target Price $205.2
| 8 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.52% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.35B USD | Price to earnings Ratio 37.63 | 1Y Target Price 205.2 |
Price to earnings Ratio 37.63 | 1Y Target Price 205.2 | ||
Volume (30-day avg) 11 | Beta 0.64 | 52 Weeks Range 122.80 - 207.84 | Updated Date 10/14/2025 |
52 Weeks Range 122.80 - 207.84 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 4.91 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 40.85% | Operating Margin (TTM) 40.93% |
Management Effectiveness
Return on Assets (TTM) 9.23% | Return on Equity (TTM) 15.61% |
Valuation
Trailing PE 37.63 | Forward PE 27.1 | Enterprise Value 4586345217 | Price to Sales(TTM) 14.89 |
Enterprise Value 4586345217 | Price to Sales(TTM) 14.89 | ||
Enterprise Value to Revenue 12.77 | Enterprise Value to EBITDA 29.02 | Shares Outstanding 28942981 | Shares Floating 22979859 |
Shares Outstanding 28942981 | Shares Floating 22979859 | ||
Percent Insiders 11.86 | Percent Institutions 97.52 |
Upturn AI SWOT
Krystal Biotech Inc
Company Overview
History and Background
Krystal Biotech Inc. was founded in 2016. It is a gene therapy company focused on developing and commercializing novel treatments for rare diseases.
Core Business Areas
- Dermatology: Focuses on developing gene therapies for dermatological diseases, including dystrophic epidermolysis bullosa (DEB).
Leadership and Structure
Krstal Biotech is led by Krish S. Krishnan as Chairman and CEO. The structure includes executive leadership across R&D, commercial, and operations.
Top Products and Market Share
Key Offerings
- VYJUVEKu2122 (beremagene geperpavec): VYJUVEK is a gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB). It is the only approved treatment of it's kind for DEB. Competitors include pain management drugs and wound care products, which do not address the underlying cause of the disease. It has a market exclusivity until at least 2037.
Market Dynamics
Industry Overview
The gene therapy industry is rapidly evolving, with increasing regulatory approvals and investment. Focus is on rare diseases with unmet needs.
Positioning
Krystal Biotech is positioned as a leader in gene therapy for dermatological diseases, with a focus on rare and orphan conditions. They have a competitive advantage as they are first to market with a gene therapy to address DEB.
Total Addressable Market (TAM)
The DEB market is estimated at $500 million to $1 Billion annually. VYJUVEK holds the exclusive gene therapy for this market.
Upturn SWOT Analysis
Strengths
- FDA Approved Product (VYJUVEK)
- Strong pipeline of gene therapy candidates
- Proprietary gene delivery platform
- Experienced management team
Weaknesses
- Reliance on a limited number of products
- High R&D costs
- Potential manufacturing challenges
- Dependence on regulatory approval
Opportunities
- Expansion into new indications and geographies
- Strategic partnerships and collaborations
- Advancements in gene therapy technology
- Increasing awareness and acceptance of gene therapy
Threats
- Competition from other gene therapy companies
- Regulatory hurdles and delays
- Adverse events or safety concerns
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- BMY
- VRTX
- CRSP
Competitive Landscape
Krystal Biotech's advantage lies in its approved gene therapy for DEB. Competitors are mainly focusing on related genetic disease or are in a different stage in development.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is unavailable.
Future Projections: Revenue is projected to increase significantly following VYJUVEK's approval. Analyst estimates vary, but generally anticipate substantial growth in the coming years.
Recent Initiatives: Approval and launch of VYJUVEK, expansion of pipeline through internal development and collaborations.
Summary
Krystal Biotech is a promising gene therapy company focused on rare dermatological diseases. With the FDA approval of VYJUVEK, they have a strong first-mover advantage in the DEB market. High R&D costs and dependence on regulatory approvals will be some challenges that Krystal Biotech will need to watch out for.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Krystal Biotech Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is an estimation.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Krystal Biotech Inc
Exchange NASDAQ | Headquaters Pittsburgh, PA, United States | ||
IPO Launch date 2017-09-20 | Founder, Chairman, President & CEO Mr. Krish S. Krishnan M.B.A., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 275 | Website https://www.krystalbio.com |
Full time employees 275 | Website https://www.krystalbio.com | ||
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.